Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients
- PMID: 11035372
- DOI: 10.1038/sj.bmt.1702532
Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients
Abstract
This retrospective study has aimed at determining the prevalence, aetiology and clinical evolution of chronic liver disease (CLD) after allogeneic bone marrow transplantation (BMT). A total of 106 patients who had been transplanted in a single institution and who had survived for at least 2 years after BMT were studied. The prevalence of CLD was 57.5% (61/106). In 47.3% of cases more than one aetiopathogenic agent coexisted. The causes of CLD were iron overload (52.4%), chronic hepatitis C (47.5%), chronic graft-versus-host disease (C-GVHD) (37.7%), hepatitis B (6.5%), non-alcoholic steatohepatitis (NASH) (4.9%), autoimmune hepatitis (AIH) (4.9%) and unknown two (3.3%). Twenty-three patients with iron overload underwent venesections which were well tolerated. An improvement in liver function tests (LFTs) was observed in 21 (91%) patients. All six patients with siderosis as the only cause of CLD normalized LFT as well as three patients with HCV infection. Clinical evolution was satisfactory for patients with GVHD, AIH, NASH and hepatitis B. At the last visit 23 patients continued with abnormal LFTs, and 19 of them were infected by the HCV. A sustained biochemical and virologic response was achieved in only one case out of six patients with CHC who received interferon. We have found that CLD is a common complication in long-term BMT survivors. The aetiology is often multifactorial, iron overload, CHC and C-GVHD being the main causes. The CLD followed a rather 'benign' and slow course in our patients as none of them developed symptoms or signs of liver failure and we did not observe an increase in morbidity or mortality in these patients, but a longer follow-up is necessary in HCV infected patients based on the natural history of this infection in other populations.
Similar articles
-
[Liver biopsy in the management of liver dysfunction after allogeneic hematopoietic stem-cell transplantation].Zhonghua Yi Xue Za Zhi. 2005 Nov 16;85(43):3062-6. Zhonghua Yi Xue Za Zhi. 2005. PMID: 16324408 Chinese.
-
[Liver dysfunction in recipients of hematopoietic stem cells. Impact on mortality].Medicina (B Aires). 2005;65(2):113-6. Medicina (B Aires). 2005. PMID: 16075803 Spanish.
-
Liver disease after bone marrow transplantation--the Taiwan experience.Transplantation. 1995 Apr 27;59(8):1139-43. Transplantation. 1995. PMID: 7732560
-
Infections with hepatotropic viruses in children treated with allogeneic bone marrow transplantation.Bone Marrow Transplant. 1998 Apr;21 Suppl 2:S75-7. Bone Marrow Transplant. 1998. PMID: 9630333 Review.
-
Gastrointestinal, hepatobiliary, pancreatic, and iron-related diseases in long-term survivors of allogeneic hematopoietic cell transplantation.Semin Hematol. 2012 Jan;49(1):43-58. doi: 10.1053/j.seminhematol.2011.10.006. Semin Hematol. 2012. PMID: 22221784 Review.
Cited by
-
Hepatic complications of hematopoietic cell transplantation.Curr Gastroenterol Rep. 2007 Mar;9(1):60-5. doi: 10.1007/s11894-008-0022-y. Curr Gastroenterol Rep. 2007. PMID: 17335679 Review.
-
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.Haematologica. 2014 Oct;99(10):1632-7. doi: 10.3324/haematol.2014.105908. Epub 2014 Jul 4. Haematologica. 2014. PMID: 24997153 Free PMC article. Clinical Trial.
-
Secondary Iron Overload and the Liver: A Comprehensive Review.J Clin Transl Hepatol. 2023 Aug 28;11(4):932-941. doi: 10.14218/JCTH.2022.00420. Epub 2023 Feb 1. J Clin Transl Hepatol. 2023. PMID: 37408825 Free PMC article. Review.
-
Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.Am J Blood Res. 2012;2(4):243-53. Epub 2012 Nov 25. Am J Blood Res. 2012. PMID: 23226624 Free PMC article.
-
Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant. 2016 Jan;51(1):89-95. doi: 10.1038/bmt.2015.204. Epub 2015 Sep 14. Bone Marrow Transplant. 2016. PMID: 26367238 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical